Please login to the form below

Not currently logged in
Email:
Password:

Sanofi promotes diabetes expert Paul Chew to chief medical officer

Takes over from Jean-Pierre Lehner who retires

Sanofi - Paul ChenSanofi has promoted Dr Paul Chew to senior VP, chief medical officer and head of global medical affairs, with effect from January 1, 2013.

Dr Chew, who is currently senior VP, chief science officer and chief medical officer at Sanofi's US division, succeeds Jean-Pierre Lehner, who retires after more than 20 years with the French pharma company.

Paying tribute to Lehner, Sanofi CEO Christopher Viehbacher said: “Jean-Pierre dedicated his career to the well-being of patients and the success of the Group. Throughout his impressive and diversified career, Jean-Pierre has made significant and lasting contributions to improve public health and has been a key contributor to Sanofi's success.”

His successor, Dr Chew, has been involved with Sanofi for 11 years, having joined Aventis Pharmaceuticals in 2001 as VP, global head of metabolism and diabetes, ahead of the company's acquisition by Sanofi in 2004.

Dr Chew then went on to serve as president of US R&D and VP therapeutic department head, metabolism, diabetes and thrombosis between 2007 and 2009 before taking over his current position.

During his time at Sanofi, Dr Chew has been heavily involved in its growing diabetes business, holding responsibility for its long-acting insulin brand Lantus (insulin glargine), and his appointment signals the company's continuing focus on the therapy area.

This has also been seen in the company's approach to social media, which is primed to focus on diabetes - one of the company's key areas for revenue growth.

“The knowledge and experience Paul has gained through his previous roles, including his work as a cardiologist, his expertise in diabetes and work within R&D make him ideally suited for this important role and continue the medical excellence which Jean-Pierre instilled within our organisation,” said Dr Elias Zerhouni, president, global R&D.

Prior to joining Aventis in 2001, Dr Chew held numerous positions at Bristol-Myers Squibb, including VP US medical affairs.

2nd October 2012

From: Research, Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics